Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB707 · 2 trials · 9 indications
Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5
Percentage of subjects with adverse events (AEs)
Percentage of subjects with serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Cohorts 1 through 4 | EXPERIMENTAL | Dose escalation and expansion cohorts: KB707 monotherapy in subjects with solid tumor malignancies affecting the lungs. |
| Cohort 5 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Keytruda in approximately 60 subjects with NSCLC. |
| Cohort 6 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Keytruda and chemotherapy in approximately 60 subjects with NSCLC. |
| Experimental: Cohort 7 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with docetaxel in approximately 50 subjects with NSCLC. |
| Name | Type | Description |
|---|---|---|
| KB707 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| Pembrolizumab (KEYTRUDA®) | DRUG | PD-1 immune checkpoint inhibitor |
| Chemotherapy | DRUG | SOC chemotherapy |
| Docetaxel | DRUG | SOC chemotherapy |
| Opdualag | DRUG | Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors) |
| KEYTRUDA ®( Pembrolizumab) | DRUG | Immunotherapy (PD-1 immune checkpoint inhibitor) |
Key Inclusion Criteria: * Age 18 years or older at the time of informed consent * Life expectancy \>12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have at least one measurable lung lesion per RECIST v1.1 at Screening * Cohorts 1 through 4 only: Histologically co...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
KB707 is an investigational monoclonal antibody developed by Krystal Biotech, Inc. for the treatment of advanced solid tumors, including non-small cell lung cancer. It is designed to target IL-2, a cytokine involved in immune system signaling, and is currently being evaluated in Phase 1 clinical trials.
KB707 is being studied for the treatment of advanced solid tumor malignancies affecting the lungs, including non-small cell lung cancer and metastatic lung cancer. It is also being evaluated in locally advanced or metastatic solid tumors such as melanoma. KB707 is investigational and has not been approved for any indication.
KB707 targets IL-2, a cytokine that plays a role in regulating immune responses. By binding to IL-2, KB707 is designed to modulate immune activity against tumor cells. This mechanism is being explored in Phase 1 trials for advanced solid tumors, including non-small cell lung cancer.
KB707 is being developed by Krystal Biotech, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol KRYS. The company is sponsoring Phase 1 clinical trials to evaluate KB707 in patients with advanced solid tumors, including lung cancer and melanoma.
KB707 is in Phase 1 clinical development. It is investigational and has not received FDA approval. The Phase 1 program includes trials evaluating the drug in advanced solid tumors, including non-small cell lung cancer and melanoma, with a combined planned enrollment of approximately 490 patients.
KB707 is being evaluated in two Phase 1 clinical trials. NCT06228326 is assessing KB707 in advanced solid tumor malignancies affecting the lungs, including non-small cell lung cancer, with a planned enrollment of 250 patients. NCT05970497 is studying KB707 in locally advanced or metastatic solid tumors, including melanoma, with a planned enrollment of 240 patients. Both trials are recruiting in the United States.